Table 1.
Patient Baseline Demographics and Clinical Characteristics
| Non-Atopic (N=272) | Atopic (N=181) | Strongly Atopic (N=94) | |
|---|---|---|---|
| Age, years, mean (SD) | 54 (13) | 50 (14) | 38 (15) |
| Gender, female, n (%) | 156 (57) | 99 (55) | 56 (60) |
| Body mass index, kg/m2, mean (SD) | 27.9 (5.6) | 28.3 (6.2) | 26.6 (5.9) |
| Duration of asthma, years, mean (SD) | 18 (13) | 21 (14) | 23 (13) |
| Proportion of patients on long-term OCS, n (%) | 75 (28) | 44 (24) | 6 (6) |
| Baseline OCS daily does, mg, mean (SD) | 11.4 (8.8) | 14.1 (11.7) | 9.3 (1.8) |
| Proportion of patients who received omalizumab | 30 (11) | 33 (18) | 10 (11) |
| Number of exacerbations in 12 months prior to screening, mean (SD) | 3.8 (2.6) | 3.5 (2.5) | 3.7 (2.9) |
| Pre-bronchodilator percent predicted FEV1, mean (SD) | 60 (18) | 62 (19) | 63 (17) |
| Baseline blood eosinophil counts, cells/μL, geometric mean (SD logs) | 300 (1.04) | 310 (0.97) | 280 (0.83) |
| Baseline total IgE level, U/mL, geometric mean (SD logs) | 85 (1.38) | 201 (1.30) | 608 (1.16) |
| Sensitivity to different allergens, n (%) | |||
| HDMsa | - | 119 (66) | 83 (88) |
| Dog dander | - | 72 (40) | 69 (73) |
| Cat dander | - | 65 (36) | 71 (76) |
| A. alternata | - | 29 (16) | 24 (26) |
| Cockroach | - | 44 (24) | 36 (38) |
Notes: aD. pteronyssinus/D. farinae combined.
Abbreviations: FEV1, forced expiratory volume in 1 second; HDM, house dust mite; IgE, immunoglobulin E; OCS, oral corticosteroid; SD, standard deviation.